Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Rhea-AI Summary

Titan Pharmaceuticals announces the sale of certain ProNeura assets to Fedson, Inc. for $2 million upfront with the potential for up to $50 million in milestone payments and single digit royalty payments on future net sales. The transaction allows Titan to focus on extracting value from their principal asset, TP-2021 for the treatment of pruritus.

Positive

• Titan Pharmaceuticals will receive $2 million upfront, strengthening their balance sheet and providing future upside potential.
• The potential for up to $50 million in milestone payments and single digit royalties on future net sales could positively affect Titan Pharmaceuticals' stock price.

Negative

• None.

Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales

SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology. The Company’s addiction portfolio consists of the Probuphine and Nalmefene implant programs. 

Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products. Titan would also receive single digit royalties on future net sales of the products. Additionally, Fedson will assume all liabilities related to a pending employment claim against Titan. The transaction is expected to close 10 days following signing of the Agreement.

“This transaction provides the opportunity for two much-needed products for the treatment of Opioid Use Disorder to continue, with the potential return of Probuphine as an available treatment option and the possible continuation of the development of the Nalmefene product, and allows Titan to renew our focus on extracting value from our principal asset, TP-2021 for the treatment of pruritus,” commented Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan Pharmaceuticals.

“We are pleased to announce the sale of these potentially lifesaving assets to Fedson,” stated David E. Lazar, Chief Executive Officer of Titan Pharmaceuticals. “The injection of this upfront non-dilutive capital, with the potential for future milestone and royalty payments not only strengthens our current balance sheet but provides future upside potential. This transaction is in line with our focus to evaluate all options to enhance shareholder value.”    

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. In December 2021, Titan commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect Schmitt's business, including the business of its subsidiary, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

Media & Investor Contacts:

Kate Beebe DeVarney, Ph.D.

President and Chief Operating Officer
(650) 989-2268

FAQ

What assets is Titan Pharmaceuticals selling to Fedson, Inc.?

Titan Pharmaceuticals is selling certain ProNeura assets, including their drug addiction products portfolio.

What is the upfront purchase price for the ProNeura assets?

The upfront purchase price for the ProNeura assets is $2 million.

What is the potential amount of milestone payments that Titan Pharmaceuticals could receive?

Titan Pharmaceuticals could receive up to $50 million in milestone payments on future net sales of the products.

Will Titan Pharmaceuticals receive royalties on future net sales of the products?

Yes, Titan Pharmaceuticals will receive single digit royalties on future net sales of the products.

What will Titan Pharmaceuticals focus on after the sale of the ProNeura assets?

Titan Pharmaceuticals will focus on extracting value from their principal asset, TP-2021, for the treatment of pruritus.